Danone omega-3 medical drink shows early Alzheimer’s benefits: RCT

By Shane STARLING contact

- Last updated on GMT

Leave it to nutrition: “This research is significant because there is limited pre-dementia data and pharmaceutical options to treat Alzheimer’s are not available."
Leave it to nutrition: “This research is significant because there is limited pre-dementia data and pharmaceutical options to treat Alzheimer’s are not available."

Related tags: Docosahexaenoic acid, Memory, Eicosapentaenoic acid

Souvenaid, the high-dose omega-3 based medical drink Danone-Nutricia launched three years ago, can help pre-dementia sufferers, a 2-year clinical trial has found.

The double blind, placebo controlled trial, part of the €6m EU-funded LipiDidiet​project, found daily consumption of Souvenaid improved the ability of early Alzheimer’s (pre-dementia) sufferers to perform everyday tasks and reduced brain shrinkage, particularly the hippocampal cranial zone.

LipiDidiet project manager Tobias Hartmann, a neurologist from the University of Saaland in Germany, told us the results were encouraging and that a new EU project called MindAD was underway observing the effects of consuming Souvenaid combined with exercise.

“This research is significant because there is limited pre-dementia data and pharmaceutical options to treat Alzheimer’s are not available,” ​said professor Hartmann.

He said the study results, presented this month at the Advances in Alzheimer's Therapy (AAT) congress in Athens, Greece, showed real-life benefits like paying bills among the 160 or so early Alzheimer’s sufferers that drank the 125 ml bottles of Souvenaid daily.

TobiasHartmann
Professor Tobias Hartmann: Encouraged by study results despite failure to show significance for primary cognition endpoint

“It had a real impact on lives,” ​the professor said. It is estimated about 47 million people suffer from Alzheimer’s globally.

But professor Hartmann expressed disappointment the trial did not achieve significance for its primary endpoint – overall cognitive function.

“But earlier estimates of cognitive decline going back ten years or more that fed this endpoint have been shown to be over-estimated, so the decline in controls was less than expected,” ​he reflected.

Study details

321 Europeans with early Alzheimer’s as determined by biomarker and behavioural assessment, were split into two groups, with the control group consuming a daily iso-caloric drink that looked and tasted like Souvenaid.

The non-achieved primary cognition endpoint was tested via 'CERAD (Consortium to Establish a Registry for Alzheimer’s Disease) 10-word immediate recall, delayed recall and recognition, category fluency and letter digit substitution test'.

The achieved secondary endpoints were measured by 'episodic memory, executive function/working memory composite and a complete composite score consisting of 16 subtests, progression to dementia, blood and CSF (cerebrospinal fluid) biomarkers, tolerance and safety'.

Significant differences were measured for hippocampal and whole-brain atrophy, and favourable effects for episodic memory.

Souvenaid

Souvenaid bottle Strawberry_EN_2012
Souvenaid sells for about €4 a bottle under prescription in most European countries.

Danone-Nutricia officially launched Souvenaid in early 2013 as a medical food in the UK and other European markets, meaning it could only be purchased via prescription under EU Food for Special Groups​laws.

It contains 1200mg of DHA (docosahexaenoic acid) and 300mg of EPA (eicosapentaenoic acid) plus uridine monophosphate, choline, phospholipids and B vitamins.

It features as a medical food in the UK, Ireland, Germany, Austria, Belgium, the Netherlands, Spain, Italy, Greece, Finland, Sweden, Australia and latin America and is about to be launched in south east Asia.

It sells under prescription for about €4 a bottle in strawberry, vanilla and cappuccino flavours.

Source:

Presented at Advances in Alzheimer's Therapy (AAT) congress, Athens, Greece; March 9-12 2016.

Authors: Tobias Hartmann et al

Related news

Show more

Related products

show more

Curcumin: Do all roads lead to gold?

Curcumin: Do all roads lead to gold?

Sabinsa Corporation | 03-Dec-2018 | Technical / White Paper

Scientific research and clinical studies in the modern era validate turmeric’s traditional use, particularly looking at curcuminoids produced by the rhizome...

Launching a unique cocoa extract processed sustainably

Launching a unique cocoa extract processed sustainably

Robertet Health & Beauty | 21-Nov-2018 | Technical / White Paper

A sweet treat and the ultimate symbol of delicacy, a mystical medicinal ingredient, an invigorating bitter beverage or even the food of the gods, cocoa...

Vegan Weight Management INNOBIO CLA TG

Vegan Weight Management INNOBIO CLA TG

INNOBIO Limited | 05-Nov-2018 | Technical / White Paper

INNOBIO® is announcing the launch of a new vegan CLA TG powder. It can easily be incorporated into a wide range of natural foods and supplements and is...

Related suppliers

1 comment

alzheirmer

Posted by oswaldo obregon,

I AM using for 27 years omega 3grs, in caps plus Antioxidants(conzima Q10,L Carnine,Alpha Lipoic Acid,Reveratrol 500 mgrs recentlyVits B ,40 mits daily walking.The same for the people with ECV deseas risk I think whit more or less exit

Report abuse

Follow us

Featured Events

View more

Products

View more

Webinars